Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | GPR3 | P46089 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.37 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
| ▸ | DDR1 | Q08345 | 5/20 | 0.36 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29948961 | 1.00 | WDR5 (0.43) | WDR5ALDH1A1POLBGAATHRB | |
| SCHEMBL2437670 | 0.81 | GPR3 (0.41) | WDR5CES1GPR3CHRM5TRPV4 | |
| SCHEMBL30567116 | 0.81 | GPR3 (0.41) | WDR5CES1GPR3CHRM5TRPV4 | |
| SCHEMBL1198803 | 0.81 | TRPV4 (0.49) | WDR5CES1GPR3CHRM5TRPV4 | |
| SCHEMBL2502219 | 0.81 | TRPV4 (0.57) | GAACES1CHRM5TRPV4KIF11 | |
| SCHEMBL3610385 | 0.80 | FFAR4 (0.46) | WDR5CES1GPR3CHRM5KIF11 | |
| SCHEMBL30540027 | 0.80 | FFAR4 (0.46) | WDR5CES1GPR3CHRM5KIF11 | |
| SCHEMBL1874207 | 0.79 | TRPV4 (0.49) | GAATRPV4CA1CA2 | |
| SCHEMBL29948804 | 0.79 | TRPV4 (0.49) | GAATRPV4CA1CA2 | |
| SCHEMBL10964642 | 0.78 | CES1 (0.41) | WDR5CES1GPR3CHRM5TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190002454-A1 | NRF2 Regulators | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-01-03 | — | — | US | disclosed |
| US-20160318917-A1 | NRF2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2016-11-03 | — | — | US | disclosed |
| US-7655641-B2 | Sulfonamide derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655641-B2 | Sulfonamide derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| EP-1597248-B1 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | LILLY CO ELI (US) | 2007-12-26 | — | — | EP | disclosed |
| EP-1597248-B1 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | LILLY CO ELI (US) | 2007-12-26 | — | — | EP | disclosed |
| US-20060217433-A1 | Sulfonamide derivatives as ppar modulators | ELI LILLY AND COMPANY (US) | 2006-09-28 | — | — | US | disclosed |
| CN-1751037-A | Sulfonamide derivatives as PPAR modulators | LILLY CO ELI (US) | 2006-03-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002454-A1 | NRF2 Regulators | NFE2L2, KEAP1, NQO1 | WDR5 2451/4885ALDH1A1 799/4885POLB 1963/4885 |
| US-20160318917-A1 | NRF2 REGULATORS | NFE2L2, KEAP1, NQO1 | WDR5 2451/4885ALDH1A1 799/4885POLB 1963/4885 |
| US-20060217433-A1 | Sulfonamide derivatives as ppar modulators | PPARD, PPARA, PPARG | WDR5 2729/4885ALDH1A1 1050/4885POLB 2436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.